The pioneers of CAR-T cell therapies

CAR-T cell therapy is a remarkably promising treatment for cancer patients. It is a type of immunotherapy where doctors collect immune cells, modify them in a laboratory, and provide them the ability to recognize and kill cancer cells. When infused into a patient, the cells get multiplied and stay in the body as “living drugs.”

Since the first historic CAR-T approvals in 2017, the following products have reached commercialization:

1. Kymriah (tisagenlecleucel)
2. Yescarta (axicabtagene ciloleucel)
3. Tecartus (brexucabtagene autoleucel)
4. Breyanzi (lisocabtagene maraleucel)
5. Abecma (idecabtagene vicleucel)
6. Carvykti (ciltacabtagene autoleucel)

These historic approvals have propelled the CAR-T market to staggering heights and fueled a frenzy of interest into CAR-T cell therapy development. To track the competitors who compose this rapidly expanding marketplace, BioInformant has released a global database of all known CAR-T cell therapy companies—currently 191 worldwide.

It takes BioInformant's analysts countless hours of research to uncover CAR-T cell therapy companies from across the globe. It also requires the translation of websites and clinical trial programs across numerous languages. 

Thankfully, we have a talented, multilingual team who is up to the task of organizing all known CAR-T companies worldwide. 

For the next 24 hours only, you can claim this database for an unusual 50% off:

Global Database of CAR-T Cell Therapy Companies, 2023

Be Great,

The BioInformant Team